The EANO Guideline on molecular testing of meningiomas for targeted therapy selection
EANO shared an article by Felix Sahm on X:
” Just Released:-
The EANO Guideline on molecular testing of meningiomas for targeted therapy selection!
Evidence-based guidance for patient care & clinical trials, and show of areas for which additional research is warranted.”
Title: EANO guideline on molecular testing of meningiomas for targeted therapy selection.
Authors: Felix Sahm. et al.
Matthias Preusser is Professor of Medical Oncology and Head of the Clinical Division of Oncology at the Medical University of Vienna.
Dr. Preusser received his medical training at the Medical University of Vienna and completed research and clinical visits at the German Cancer Center (DKFZ) in Heidelberg, Germany, and the Memorial Sloan-Kettering Cancer Center.
He is a Chair-elect of the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumour Group and serves as President of the European Association for Neuro-Oncology (EANO).
Dr. Preusser has also served as Chair of the ESMO Young Oncologists Committee. He is currently a member of the ESMO Fellowship Committee, the ESMO Faculty for CNS Tumours and he is also a Subject Editor in the ESMO Guidelines Committee and a member of the ESMO Nomination Committee.
He also serves as Deputy Editor of ESMO Open. His research focuses on biomarkers and therapy in brain tumours.
For More Updates, Follow OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023